BDX Stock Forecast & Price Target

Becton Dickinson's financial performance demonstrates resilience and growth, with Medical Surgical Solutions (MMS) reporting sales of $888 million in FQ3'25, reflecting a year-over-year increase of 5.3% driven by strong demand in Infusion Systems and growth in Dispensing Solutions and Pharmacy Automation. The company's MedTech business has consistently expanded at a rate exceeding 6% annually since the initiation of the BD 2025 strategy, accompanied by improving margins. Furthermore, the MDS segment achieved fiscal year 2024 sales of $4.43 billion, marking a 3.2% increase year-over-year, underscoring the company's robust market position.

Becton Dickinson's reaffirmed organic revenue growth outlook of 3.0-3.5% for fiscal year 2025 represents a decline from the previous forecast of 4.0-4.5%, indicating potential challenges in meeting growth expectations. In the third quarter of fiscal year 2025, the company reported sales of $1.25 billion, a 1.1% year-over-year decline when excluding foreign exchange effects, driven by weaknesses in its Biosciences and Diagnostic Solutions segments. Additionally, external pressures such as volume-based procurement challenges in China and reduced government research funding are further contributing to downward growth momentum, reflecting broader market headwinds.